Sanara MedTech

What Sanara MedTech does

Sanara MedTech Inc. (NASDAQ: SMTI) is a Fort Worth, Texas-based medical technology company that develops and commercializes FDA-cleared surgical and wound care products for hospitals, ambulatory surgery centers, and post-acute care settings. Following a November 2025 strategic realignment that discontinued the Tissue Health Plus program, the company operates as a pure-play surgical business focused on reducing surgical site infections, periprosthetic joint infections, and wound-healing complications across orthopedic, spine, trauma, plastic, and general surgery procedures.

Name

Sanara MedTech

Legal name

Sanara MedTech, Inc.

Website

https://sanaramedtech.com

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Orthobiologic Surgical Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Surgical wound care
• Orthopedic biologics
• Bone graft substitutes
• Surgical irrigation solutions
• Amniotic tissue allografts

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Product sales (surgical implants, irrigation solutions, grafts): Sanara generates revenue primarily through one-time sales of FDA-cleared surgical hardware and consumable products (CellerateRX, BIASURGE, FORTIFY, TEXAGEN, ALLOCYTE, BiFORM, ACTIGEN, OsStic) sold to hospitals, ambulatory surgery centers, and distributors. The company transitioned to a pure-play surgical business in 2025 following discontinuation of the Tissue Health Plus program.
2. Distribution and channel partner sales: Sanara sells through a network of over 450 contracted distributor partners and a field sales team of approximately 40 representatives covering U.S. healthcare facilities (over 1,450 accounts) with approvals at GPO, government, and facility levels.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Sanara MedTech develops, markets, and distributes a portfolio of FDA-cleared surgical and biologic products sold to hospitals, ambulatory surgery centers, and physicians. Its portfolio spans hydrolyzed collagen wound adjuncts (CellerateRX), PHMB-based intraoperative irrigation (BIASURGE), extracellular matrix soft tissue grafts (FORTIFY TRG/FLOWABLE), amniotic membrane allografts (TEXAGEN), viable cellular bone matrices (ALLOCYTE Plus), and bioactive bone graft composites (BiFORM and ACTIGEN), with the OsStic bone bioadhesive in late-stage pipeline.

Product overview

Sanara MedTech Inc. is a medical technology company that develops and commercializes a portfolio of FDA-cleared surgical and wound care products organized around four pillars: (1) hydrolyzed collagen surgical adjuncts led by CellerateRX® Surgical Powder and CellerateRX® Gel, (2) advanced surgical irrigation led by BIASURGE® Advanced Surgical Solution, (3) extracellular-matrix-based soft tissue repair grafts including FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix, and (4) an orthobiologics line spanning TEXAGEN® Amniotic Membrane Allograft, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, and ACTIGEN™ Verified Inductive Bone Matrix. The OsStic™ bone bioadhesive is the company's pipeline product, planned for U.S. commercial launch in Q1 2027 pending FDA clearance. Following its November 2025 strategic realignment, the portfolio is now focused entirely on the surgical market after discontinuation of the Tissue Health Plus segment.

Differentiator

Problem solved

Functional benefit

Brands

• CellerateRX Surgical Powder: FDA-cleared hydrolyzed collagen powder for management of acute and chronic wounds, including surgical wounds.
• CellerateRX Gel
• BIASURGE Advanced Surgical Solution
• FORTIFY TRG Tissue Repair Graft
• FORTIFY FLOWABLE Extracellular Matrix
• TEXAGEN Amniotic Membrane Allograft
• ALLOCYTE Plus Advanced Viable Bone Matrix
• BiFORM Bioactive Moldable Matrix
• ACTIGEN Verified Inductive Bone Matrix
• OsStic

Products and services

• CellerateRX Surgical Powder FDA-cleared hydrolyzed Type I collagen powder indicated for management of acute and chronic wounds (surgical, partial/full-thickness, traumatic, venous stasis, arterial, diabetic ulcers, first- and second-degree burns); provides soluble collagen to support wound inflammation, perfusion, and breaking strength of repaired tissue.
• CellerateRX Gel Hydrolyzed collagen gel formulation of the CellerateRX line for wound and skin care applications.
• BIASURGE Advanced Surgical Solution FDA-cleared, no-rinse intraoperative irrigation solution using polyhexamethylene biguanide (PHMB) in synergy with surfactants/additives; demonstrated rapid (60-second) bactericidal efficacy against a panel of microorganisms including MRSA and Pseudomonas aeruginosa, prevention/eradication of biofilms on implantable materials, and compatibility with bone cements, adhesives, sealants, and prosthetic metals.
• FORTIFY TRG Tissue Repair Graft Decellularized extracellular matrix (ECM) tissue repair graft used as an adjunct in tendon repairs (Achilles, patellar, quadriceps) and other soft tissue reinforcement procedures; designed to provide biocompatibility, mechanical properties mimicking native tissue, suture retention, and host tissue integration.
• FORTIFY FLOWABLE Extracellular Matrix Flowable extracellular matrix product for soft tissue reinforcement applications across surgical specialties.
• TEXAGEN Amniotic Membrane Allograft Amniotic membrane allograft used in surgical applications for wound and soft tissue coverage.
• ALLOCYTE Plus Advanced Viable Bone Matrix Cryopreserved cellular bone allograft providing osteogenic, osteoconductive, and osteoinductive properties for bone grafting in spine and orthopedic surgical procedures; uses proprietary non-DMSO cryopreservative to bio-coat cell membranes, eliminating rinsing/decanting and avoiding DMSO cytotoxicity.
• BiFORM Bioactive Moldable Matrix Bioactive glass / collagen / anorganic bone mineral composite (30% 45S5 bioactive glass, 20% bovine Type I collagen, 50% bovine anorganic bone mineral); demonstrated approximately 2x higher fusion results than Vitoss BA at 14 weeks in a rabbit posterolateral spinal fusion model and 2.5x more calcium phosphate deposition in simulated body fluid.
• ACTIGEN Verified Inductive Bone Matrix Verified inductive bone matrix offering supporting osteoinductive and osteoconductive functions for bone repair and fusion procedures in spine and orthopedic surgery.

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered major, moderate and historical.

• Vizient Inc.majorGTM or Marketing Partner · 1 January 2026Vizient awarded Sanara's BIASURGE Advanced Surgical Solution an Innovative Technology contract effective January 1, 2026. The contract provides Vizient's network of healthcare facilities access to BIASURGE at contracted pricing, was recommended by hospital experts serving on Vizient's client-led councils, and gives Sanara access to a GPO representing over $156 billion in annual purchasing volume.
• Biomimetic Innovations LtdmajorStrategic or Co-development Partner · 10 December 2025Biomimetic Innovations Ltd is Sanara MedTech's co-development partner for the OsStic bone bioadhesive technology. Following recent milestones and FDA Breakthrough Device designation, the partners are progressing toward a U.S. market launch in Q1 2027 pending FDA clearance to address unmet needs in fracture management; recent FDA patent grants have been announced.
• BMI (Bone Matrix Inc. / strategic alliance partner)moderateStrategic or Co-development Partner · 24 March 2025Sanara MedTech announced a strategic alliance with BMI as part of its Q4 and full-year 2025 results, alongside its Vizient contract win for BIASURGE; specific scope and structure of the BMI alliance are not detailed in the source material beyond being identified as a key operational milestone.
• Scendia Biologics, LLChistoricalStrategic or Co-development Partner · 1 July 2022Sanara MedTech completed its acquisition of Scendia Biologics, LLC on July 1, 2022, for $7.4 million, expanding Sanara's biologic product portfolio and geographic reach in wound care markets.
• Precision Healing Inc.historicalStrategic or Co-development Partner · 4 April 2022Sanara MedTech closed its merger to acquire Precision Healing Inc. in Fort Worth, Texas in April 2022, expanding Sanara's product pipeline in wound and skincare markets, including telehealth services.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MTF Biologics: MTF Biologics is a nonprofit tissue bank that develops and distributes allograft-based orthobiologics, wound care, and sports medicine products used in surgical settings. Directly comparable to Sanara's TEXAGEN amniotic membrane, ALLOCYTE Plus cellular bone matrix, and FORTIFY ECM franchises; serves the same orthopedic, spine, and plastic surgery customer base.
• Anika Therapeutics: Anika Therapeutics is a direct peer in orthobiologics and surgical hyaluronic acid/regenerative products, with offerings in joint preservation, bone repair, and ENT surgery. Comparable to Sanara's orthobiologics and soft tissue repair portfolio (FORTIFY ECM grafts, BiFORM bioactive glass composite), targeting similar orthopedic and sports medicine surgeon customers.
• Organogenesis Holdings: Organogenesis is a direct peer in advanced wound care and surgical biologics, with leading products Apligraf and Dermagraft for wound management and PuraPly for surgical applications. Comparable to Sanara in addressing SSI prevention, chronic wound healing, and surgical soft tissue coverage through biologic and regenerative technologies.
• MiMedx Group: MiMedx is a direct competitor in surgical and wound care biologics, with a portfolio of placental tissue allografts (EpiFix, AmnioFix, AmnioCord) and orthobiologics used in surgical and wound healing applications. Highly comparable to Sanara's TEXAGEN amniotic membrane and wound care franchises; both target orthopedic, spine, and wound care surgeons with biologic solutions.
• Vericel Corporation: Vericel develops advanced cell therapies and orthobiologics for the surgical sports medicine and burn/wound care markets (MACI for cartilage repair, Epicel for burns). Comparable to Sanara's orthobiologics franchise (ALLOCYTE Plus cellular bone matrix) given the shared focus on cellular/viable allografts sold into orthopedic and surgical specialists.

Broad incumbents

• Smith+Nephew: Smith+Nephew is a broad incumbent with significant wound care (Allevyn, PICO negative pressure), orthopedics, and sports medicine businesses. Comparable to Sanara in advanced wound management and surgical adjacencies serving orthopedic surgeons; competes for hospital budgets and surgical adjacencies used in joint replacement, spine, and trauma procedures.
• Integra LifeSciences: Integra LifeSciences is a larger, established medical technology company with significant overlap in regenerative technologies, wound care, and surgical products (including DuraGen, Integra Dermal Regeneration Template, and amniotic membrane allografts). Comparable to Sanara across orthobiologics and surgical soft tissue repair, but with a much broader portfolio spanning neurosurgery, ENT, and reconstructive surgery.
• Stryker Corporation: Stryker is a broad incumbent in orthopedics, surgical equipment, and surgical biologics (through its Wright Medical acquisition), serving the same orthopedic, spine, and trauma surgeons as Sanara. While much larger, Stryker competes in adjacent bone graft, soft tissue, and surgical irrigation categories where Sanara's BIASURGE, BiFORM, and ALLOCYTE Plus are sold.
• Coloplast: Coloplast operates a sizable Wound & Skin Care business (Biatain, Comfeel) selling advanced wound dressings and skin care products into hospitals and post-acute care settings. Comparable to Sanara's wound care surgical adjuncts (CellerateRX) targeting the same SSI prevention and chronic wound healing use cases, though Coloplast is a much larger, diversified medtech incumbent.

Emerging players

• Surmodics: Surmodics is a smaller medical device and in-vitro diagnostics company with a vascular intervention drug-coated balloon business and a strategic move into orthopedic surgical surface treatments. Adjacent peer to Sanara in surgical medical devices with overlapping customer base of vascular and orthopedic specialists; comparable scale and growth-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sanaramedtech
• Facebookfacebook.com/sanaramedtech
• LinkedInlinkedin.com/company/sanara-medtech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanara MedTech